Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Lavelle D, Vaitkus K, Ling Y, Ruiz MA, Mahfouz R, Ng KP, Negrotto S, Smith N, Terse P, Engelke KJ, Covey J, Chan KK, Desimone J, Saunthararajah Y. Lavelle D, et al. Among authors: saunthararajah y. Blood. 2012 Feb 2;119(5):1240-7. doi: 10.1182/blood-2011-08-371690. Epub 2011 Dec 7. Blood. 2012. PMID: 22160381 Free PMC article.
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y. Mahfouz RZ, et al. Among authors: saunthararajah y. Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3. Clin Cancer Res. 2013. PMID: 23287564 Free PMC article.
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R, Lavelle D, Gowhari M, Pacini M, Krauz L, Hassan J, Ibanez V, Ruiz MA, Ng KP, Woost P, Radivoyevitch T, Pacelli D, Fada S, Rump M, Hsieh M, Tisdale JF, Jacobberger J, Phelps M, Engel JD, Saraf S, Hsu LL, Gordeuk V, DeSimone J, Saunthararajah Y. Molokie R, et al. Among authors: saunthararajah y. PLoS Med. 2017 Sep 7;14(9):e1002382. doi: 10.1371/journal.pmed.1002382. eCollection 2017 Sep. PLoS Med. 2017. PMID: 28880867 Free PMC article. Clinical Trial.
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Hill B, Jagadeesh D, Pohlman B, Dean R, Parameswaran N, Chen J, Radivoyevitch T, Morrison A, Fada S, Dever M, Robinson S, Lindner D, Smith M, Saunthararajah Y. Hill B, et al. Among authors: saunthararajah y. Semin Hematol. 2021 Jan;58(1):35-44. doi: 10.1053/j.seminhematol.2020.11.008. Epub 2020 Dec 14. Semin Hematol. 2021. PMID: 33509441 Free PMC article. Clinical Trial.
Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.
Awada H, Mahfouz RZ, Kishtagari A, Kuzmanovic T, Durrani J, Kerr CM, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, Maciejewski JP, Saunthararajah Y. Awada H, et al. Among authors: saunthararajah y. Br J Haematol. 2020 Mar;188(6):924-929. doi: 10.1111/bjh.16281. Epub 2019 Nov 17. Br J Haematol. 2020. PMID: 31736067 Free PMC article.
Noncytotoxic differentiation treatment of renal cell cancer.
Negrotto S, Hu Z, Alcazar O, Ng KP, Triozzi P, Lindner D, Rini B, Saunthararajah Y. Negrotto S, et al. Among authors: saunthararajah y. Cancer Res. 2011 Feb 15;71(4):1431-41. doi: 10.1158/0008-5472.CAN-10-2422. Epub 2011 Feb 8. Cancer Res. 2011. PMID: 21303982 Free PMC article.
164 results